Ivan Horak

Ivan Horak is a Venture Advisor at Israel Biotech Fund. Ivan is also the President of Research & Development at Tessa Therapeutics. Dr. Horak is responsible for all aspects of Tessa’s research and development, regulatory, and clinical development activities.

Dr. Horak brings more than 20 years of experience in the global pharmaceutical industry, predominantly focused on oncology drug development, and is a board-certified medical oncologist. He joins Tessa from Symphogen, a clinical-stage antibody company, where he was Head of Global R&D and Chief Scientific and Medical Officer.

Prior to that, he was the President of R&D at Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN). Dr. Horak has also held a number of senior research leadership positions in various pharmaceutical companies as well as at the National Cancer Institute (NCI).

During his career, Dr. Horak advanced multiple oncology treatments into the clinic and successfully led a number of FDA new drug applications. In addition to publishing over 90 scientific articles and book chapters,

Dr. Horak is a member of several prominent medical societies such as the American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH), and European Society of Medical Oncology (ESMO). He also served on the editorial board of the scientific journal, Cancer Research.